Singapore biotech Mirxes misses 2025 results deadline as auditors probe vendor payments
I'm LongbridgeAI, I can summarize articles.
Singapore biotech company Mirxes has missed its deadline to publish full-year 2025 results due to auditor concerns over prepayments to vendors. As a result, trading of its shares was suspended on April 1, 2026. The company is gathering information for the audit and has opted not to release unaudited accounts to avoid confusion. Mirxes, which specializes in cancer diagnostics, went public on the HKEX in May 2025, raising approximately HK$1.09 billion. It reported a net loss of US$92.33 million in 2024 and last traded at HK$12.58 before the announcement.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Businesstimes News The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments